Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward.
In the global market for advanced metabolic treatments, two major players are finding themselves in the spotlight: Eli Lilly & Co. (LLY) and Novo Nordisk A/S (NVO). Both companies are scaling up their manufacturing capacities to meet the growing demand for their products. Eli Lilly primarily focuses on drug discovery and marketing in 90 countries, while Novo Nordisk leverages its Danish roots to lead in diabetes and rare disease therapies.
Eli Lilly's financial performance in the fiscal year ended September 30, 2026, has been robust, with revenue reaching approximately $86.5 billion, representing a revenue growth of around 45.5%. Net income for the same period was around $27.6 billion. The company maintains a current ratio of nearly 1.6x and a debt-to-equity ratio of roughly 1.6x, indicating a manageable level of debt relative to its equity. Eli Lilly's free cash flow for the fiscal year ended December 31, 2025, was approximately $9.0 billion.
Novo Nordisk, on the other hand, has a different valuation profile. Its revenue reached about $49.0 billion in the fiscal year ended September 30, 2026, reflecting a revenue growth of approximately 5.7%. Net income was roughly $16.6 billion. Novo Nordisk's debt-to-equity ratio is roughly 0.7x, and its current ratio is around 0.8x, indicating that current assets cover 80% of current liabilities. The company's free cash flow for the same period was approximately $4.3 billion.
Both companies face various challenges. Eli Lilly must navigate significant research and development risks, legal challenges regarding drug pricing, and revenue concentration concerns. Novo Nordisk deals with intense competition, strict regulatory oversight, and pricing pressure from government healthcare systems and private insurers. However, Novo Nordisk appears to be more affordable on a relative basis, with valuation multiples sitting well below those of Eli Lilly.
In summary, both Eli Lilly and Novo Nordisk are formidable players in the advanced metabolic treatment market, each with its own strengths and challenges. Investors should carefully consider their investment goals and risk tolerance when deciding between these two companies for their long-term portfolios.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.